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In Brief
N-cyanoamidine neonicotinoid
insecticides are much less toxic to
honeybees and bumble bees than
N-nitroguanidine compounds. Manjon
et al. show that this results from
differences in their efficiency of
metabolism by cytochrome P450s of the
CYP9Q subfamily, demonstrating their
role as key determinants of bee sensitivity
to this insecticide class.
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The impact of neonicotinoid insecticides on the
health of bee pollinators is a topic of intensive
research and considerable current debate [1]. As
insecticides, certain neonicotinoids, i.e., N-nitrogua-
nidine compounds such as imidacloprid and thiame-
thoxam, are as intrinsically toxic to bees as to the
insect pests they target. However, this is not the
case for all neonicotinoids, with honeybees orders
of magnitude less sensitive to N-cyanoamidine com-
pounds such as thiacloprid [2]. Although previous
work has suggested that this is due to rapid meta-
bolism of these compounds [2–5], the specific
gene(s) or enzyme(s) involved remain unknown.
Here, we show that the sensitivity of the two most
economically important bee species to neonicoti-
noids is determined by cytochrome P450s of the
CYP9Q subfamily. Radioligand binding and inhibitor
assays showed that variation in honeybee sensitivity
to N-nitroguanidine and N-cyanoamidine neonicoti-
noids does not reside in differences in their affinity
for the receptor but rather in divergent metabolism
by P450s. Functional expression of the entire CYP3
clade of P450s from honeybees identified a single
P450, CYP9Q3, that metabolizes thiacloprid with
high efficiency but has little activity against imidaclo-
prid. We demonstrate that bumble bees also exhibit
profound differences in their sensitivity to different
neonicotinoids, and we identify CYP9Q4 as a func-
tional ortholog of honeybee CYP9Q3 and a keymeta-
bolic determinant of neonicotinoid sensitivity in this
species. Our results demonstrate that bee pollinators
are equipped with biochemical defense systems that
define their sensitivity to insecticides and this knowl-
edge can be leveraged to safeguard bee health.Current Biology 28, 1137–1143, A
This is an open access article undRESULTS AND DISCUSSION
Bees carry out vital ecosystem services by pollinating wild plants
and economically important crops but, in doing so, are exposed
to a wide variety of natural and synthetic xenobiotics (including
pesticides) [6]. Understanding the molecular defense systems
that bees use to protect themselves from these potential toxins
and their effectiveness and specificity provides important knowl-
edge that can be used to avoid negative off-target effects [7].
Previous studies have demonstrated that honeybees exhibit
marked differences in their sensitivity to different pesticides.
Indeed, certain compounds display such low acute toxicity to
bees that they are used as in-hive treatments by beekeepers
against parasitic Varroa mites [6]. This differential sensitivity ex-
tends to neonicotinoid insecticides, with honeybees exhibiting
profound differences in their sensitivity to N-nitroguanidine and
N-cyanoamidine neonicotinoids [2]. In this study, we used imida-
cloprid and thiacloprid as exemplars of each class and first
examined whether this differential sensitivity extends to bumble
bees (Bombus terrestris), the second-most economically impor-
tant bee pollinator species worldwide. In both contact and oral
bioassays, significant (> 500-fold) differences were observed
in the sensitivity of bumble bees to the two compounds (Fig-
ure 1A, Table S1). Based on these results and previous data
for honeybees [9, 10], imidacloprid is categorized as ‘‘highly
toxic’’ to both bumble bees and honeybees, according to the
U.S. Environmental Protection Agency (EPA) (Figure 1A) [8].
In contrast, thiacloprid is categorized as ‘‘slightly toxic’’ or
‘‘practically non-toxic’’ to both bee species depending on the
route of exposure (Figure 1A) [10].
The molecular basis of the differences in sensitivity of bees to
these neonicotinoids could reside in differences in their affinity
for the target site, the nicotinic acetylcholine receptor (nAChR),
or from differences in the speed and efficiency of their meta-
bolism. To examine the role of the former in intrinsic bee toler-
ance to thiacloprid, we carried out radioligand binding assays
using honeybee and bumble bee head membrane preparations,
an enriched source of nAChRs, using tritiated imidacloprid
and examined the displacement of [3H]-imidacloprid by bothpril 2, 2018 ª 2018 The Author(s). Published by Elsevier Ltd. 1137
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. Toxicodynamics and Pharmacokinetics of Neonicotinoid Sensitivity in Two Bee Species
(A) LD50 values for imidacloprid and thiacloprid upon oral and topical application in A. mellifera and B. terrestris. Sensitivity thresholds are depicted according to
EPA toxicity ratings [8]. Data for A. mellifera is taken from [9, 10], data for B. terrestris was generated in this study. Error bars display 95% CLs (n = 4).
(B) Specific binding of thiacloprid and imidacloprid to both A. mellifera and B. terrestris nAChRs. Error bars display standard deviation (n = 3).
(C) Sensitivity of A-p-methoxy-. mellifera to imidacloprid and thiacloprid before and after pretreatment with the insecticide synergist ABT (aminobenzotriazole).
Error bars display 95% CLs (n = 3).
See also Table S1.unlabelled imidacloprid and thiacloprid. As shown in Figure 1B,
in the case of both bee species, both imidacloprid and thiaclo-
prid bind with nM affinity, and no significant difference was
seen in the specific binding of either compound at the receptor
(IC50 of 1.2, [95% CI 0.97, 1.6] and 1.1 nM [95% CI 0.94, 1.6]
for imidacloprid and thiacloprid respectively for honeybees,
and IC50 of 0.71 [95% CI 0.62, 0.82] and 0.62 nM [95% CI
0.50, 0.77] for imidacloprid and thiacloprid for bumble bees).
This finding clearly demonstrates that the differences in bee
sensitivity to these two neonicotinoids is not a consequence of
variation in their affinity for the nAChR.
The use of insecticide synergists that inhibit insect metabolic
enzyme systems has provided evidence that one or more mem-
bers of the cytochrome P450 superfamily are responsible for the
tolerance of honeybees to thiacloprid [2]. Indeed, Iwasa et al. [2]
demonstrated that the P450 inhibitors piperonyl butoxide (PBO),
triflumizole, and propiconazole increased honeybee sensitivity
to thiacloprid by 154-, 1,141- and 559-fold, respectively, but
had almost no effect on honeybee sensitivity to imidacloprid.
To explore this further, we used 1-aminobenzotriazole (ABT), a
nonspecific suicide inhibitor of P450s that has been used widely
in mammalian systems to distinguish P450-mediated meta-
bolism from non-P450-mediated metabolism in vitro [11, 12].
Honeybees pretreated with ABT became > 170-fold more sensi-
tive to thiacloprid but only 2.7-foldmore sensitive to imidacloprid
(Figure 1C), supporting the view that P450s underlie the variation
in the sensitivity of this bee species to these two compounds.
Likewise, insecticide bioassays of bumble bees after treatment
with PBO resulted in a significant 4.2-fold increase in the sensi-
tivity of bumble bees to thiacloprid but no significant shift in
sensitivity to imidacloprid (Table S1). Thus, we demonstrate
that P450s also appear to be an important determinant of neon-
icotinoid sensitivity in bumble bees. The level of synergism we
observed in bumble bees is significantly lower than that reported
by Iwasa et al. [2] using the same inhibitor (see above); thismay in
part result from differences in methodology used (contact versus
oral insecticide bioassays) and/or differences in the ability of this
synergist to inhibit the relevant P450 enzymes.1138 Current Biology 28, 1137–1143, April 2, 2018Insect P450 genes fall into four major clades, and enzymes
from each of these clades have been linked to insecticide resis-
tance or to the metabolism of xenobiotics [13]. However, mem-
bers of the CYP3 clade, particularly those of the CYP6 and
CYP9 families, have been most frequently linked to xenobiotic
detoxification across a range of insect species [13–15]. There-
fore, to explore which honeybee P450(s) are responsible for
thiacloprid metabolism, 27 of the 46 honeybee P450 genes,
comprising the entire CYP3 clade, were individually coex-
pressed with house fly P450 reductase (CPR) in an insect cell
line. Incubation of purified microsomal preparations containing
each P450 and CPR with thiacloprid and analysis of the metab-
olites produced by liquid chromatography tandem mass spec-
trometry (LC-MS/MS) identified a single P450, CYP9Q3, as the
highly efficient metabolizer of thiacloprid (primarily to 5-hydroxy
thiacloprid) (Figures 2A, S1, and S2). Topical bioassays of honey-
bees using 5-hydroxy thiacloprid revealed reduced toxicity of
this metabolite (LD50-value of > 100 mg/bee) relative to the parent
compound (Figure 1A). Three other P450s—CYP6AS5, CYP9Q1,
and CYP9Q2—showed weak activity against thiacloprid, but this
was at least > 10-fold lower than that seen for CYP9Q3 (Fig-
ure 2A). Repeating these assays using imidacloprid revealed
that only CYP9Q1–3 exhibit any capacity tometabolize this com-
pound but at much lower efficiency than exhibited for thiacloprid
(Figure 2A). To provide additional evidence that CYP9Q3 is the
primary honeybee P450 that confers tolerance to thiacloprid
in vivo, we created a series of transgenic Drosophila lines
expressing honeybee CYP9Q1, CYP9Q2, or CYP9Q3. Flies ex-
pressing the CYP9Q3 transgene showed a marked (> 10-fold)
and significant resistance to thiacloprid compared to control flies
of the same genetic background without the transgene in insec-
ticide bioassays (Figure 2D). Flies expressing CYP9Q1 showed
no change in sensitivity to thiacloprid compared to controls,
and flies expressing CYP9Q2 showed a significant but more
modest (3.5-fold) resistance to thiacloprid (Figure 2D). In bioas-
says using imidacloprid, no significant differences in sensitivity
were observed between flies with any of the three transgenes
and control flies consistent with the low efficiency of imidacloprid
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Figure 2. Identification of Neonicotinoid Metabolising P450s in Honeybee and Bumble Bee
(A and C) (A) Thiacloprid and imidacloprid hydroxylation by recombinantly expressed P450s of the A. melliferaCYP3 clade and (C) the CYP9 family inB. terrestris.
The production of the hydroxymetabolite of each insecticide is displayed per mg of P450 protein (NS, not significant; **Pc < c0.01, ***Pc < c0.001; Welch’s t test).
Error bars display standard deviation (n = 3).
(B) Phylogenetic tree with branch bootstrap values for A. mellifera (green) and B. terrestris (blue) P450 genes. Genes are grouped according to their adscription to
different P450 clades. Branches within the CYP3 clade marked with a red dot indicate the position of A. melliferaCYP9Qs and their closest B. terrestris orthologs
involved in thiacloprid metabolism, as shown in (A), (C), and (D).
(D) Resistance ratio (RR) of transgenic Drosophila strains expressing A. mellifera AmCYP9Q1–3 or B. terrestris BtCYP9Q4-5 transgenes to thiacloprid and
imidacloprid compared to a control line (flies of the same genetic background but without the transgene). Significance is referenced against this control line and
based on non-overlapping 95% fiducial limits of LC50 values (n = 3).
See also Figures S1, S2, and S3.metabolism observed in vitro (Figure 2D). Taken together, these
results demonstrate unequivocally that the transcription of
CYP9Q3 confers strong intrinsic tolerance to thiacloprid, but
not to imidacloprid.
To identify potential functional orthologs of honeybeeCYP9Q3
in the bumble bee, we compared P450s identified in the
sequenced genome of B. terrestris [16] with CYP9Q1–3. Phylo-
genetic analysis of the B. terrestris CYPome revealed five candi-date genes subsequently named asCYP9P1,CYP9P2,CYP9R1,
CYP9Q4, and CYP9Q5 that cluster with honeybee CYP9Q1–3
(Figure 2B). Of these, CYP9Q4 and CYP9Q5 show the greatest
sequence identity to honeybee CYP9Q1–3 (Figure S3). Func-
tional expression of these five P450s in vitro revealed that only
CYP9Q4 and CYP9Q5 metabolize thiacloprid to its 5-hydroxy
form (Figure 2C), with subsequent enzyme kinetic assays con-
firming that CYP9Q4 metabolizes thiacloprid more efficientlyCurrent Biology 28, 1137–1143, April 2, 2018 1139
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Figure 3. Metabolism of Acetamiprid and
Model Substrates by Honeybee and Bumble
Bee CYP9Q Subfamily P450s
(A and C) Acetamiprid N-desmethylation by re-
combinantly expressed CYP9Q1–3 of A. mellifera
and (C) CYP9Q4–5 ofB. terrestris. The production of
N-desmethylated acetamiprid is displayed per mg of
protein. Error bars display standard deviation (n = 3).
(B and D) (B) Activity of CYP9Q1–3 and (D)
CYP9Q4–5 against different fluorescent coumarin
model substrates. Error bars display standard
deviation (n = 3). Abbreviations: MC, 7-methox-
ycoumarin; MFC, 7-methoxy-4-trifluoromethyl
coumarin; EC, 7-ethoxy coumarin; BFC, 7-benzy-
loxy-4-trifluoromethyl coumarin; EFC, 7-ethoxy-4-
trifluoromethyl coumarin; BOMFC, 7-benzylox-
ymethoxy-4-trifluoromethyl coumarin; MOBFC,
7-p-methoxy-benzyloxy-4-trifluoro coumarin.than CYP9Q5 (Figure S2). Further functional validation of these
two P450s by expression in transgenic Drosophila revealed
that flies expressing CYP9Q4 exhibited significant (5-fold)
resistance to thiacloprid compared to controls, whereas flies ex-
pressing CYP9Q5 showed no change in sensitivity (Figure 2D).
As for honeybee CYP9Q1–3, no significant differences were
observed in the sensitivity of flies expressing either CYP9Q4 or
CYP9Q5 to imidacloprid compared to controls (Figure 2D).
Thus, these findings demonstrate that members of the CYP9Q
subfamily also confer tolerance to thiacloprid in B. terrestris.
To further explore the substrate specificity of CYP9Q1–5, we
tested their functional activity against a range of fluorescent
model substrates and acetamiprid, a second N-cyanoamidine
neonicotinoid that also has low acute toxicity to honeybees
and is very rapidly metabolized in vivo [4]. Against coumarin
model substrates, honeybee CYP9Q1–3 show a preference for
bulkier molecules such as BFC and BOMFC, with CYP9Q1 and
CYP9Q3 both showing highest specific activity for BFC (Fig-
ure 3B). In addition, CYP9Q3 demonstrated a pattern of broader
substrate specificity than the other two P450s, suggestive of a
more promiscuous active site (Figure 3B). These results con-
trasted with bumble bee CYP9Q4 and CYP9Q5, which showed
no activity against BFC and, in the case of CYP9Q4, a noticeably
reduced substrate specificity with activity against just two of the
model substrates tested (MFC andMOBFC) (Figure 3D). Incuba-
tion of recombinant CYP9Q1–5 with acetamiprid followed by
LC-MS/MS analyses revealed that all five P450s have the capac-
ity to metabolize this compound to N-desmethyl acetamiprid,
with CYP9Q2–5 exhibiting the highest activity (Figures 3A and
3C). Thus, our data demonstrate that the rapid metabolism of
acetamiprid reported in vivo [4] is likely mediated, at least in
part, by P450s of the CYP9Q subfamily.
The CYP9Q subfamily of P450s has been implicated in
the metabolism of xenobiotics previously, with honeybee1140 Current Biology 28, 1137–1143, April 2, 2018CYP9Q1–3 all found to metabolize the py-
rethroid tau-fluvalinate and the organo-
phosphate coumaphos, two insecticides
that show marked selectivity for mites
(i.e., Varroa) over bees [15]. Our findings
reveal that in both honey bees and bumblebees, this P450 subfamily contains potent metabolizers of
certain neonicotinoid insecticides, thus explaining the low acute
toxicity of thiacloprid and acetamiprid. In humans, just a handful
of the 57 functional P450s are responsible for the biotransforma-
tion of most foreign chemicals; for example, CYP3A4 and
CYP2D6 together are responsible for the metabolism of > 50%
of clinically used drugs [17]. The finding that members of the
bee CYP9Q subfamily have the capacity to metabolize com-
pounds belonging to three different insecticide classes suggests
that theymay act as functional insect equivalents of these human
P450s and thus are critically important in defining the sensitivity
of eusocial bees to xenobiotics.
To identify the primary sites of CYP9Q-mediated detoxifica-
tion, P450 expression was assessed in bee body parts and
dissected tissues that are commonly involved in xenobiotic
detoxification [18] by quantitative PCR (qPCR). CYP9Q3 was
expressed at high levels in the honeybee brain and Malpighian
tubules (Figure 4A), the latter finding consistent with a previous
studywhich examined expression in honeybee tissues, including
the Malpighian tubules, by RNA-seq [19]. In B. terrestris,
CYP9Q4 and CYP9Q5 showed marked differences in their
pattern of spatial expression, with CYP9Q4 highly expressed in
the brain (> 60-fold greater than in the other tissues tested)
andCYP9Q5 expressed at relatively uniform levels in themidgut,
Malpighian tubules, and brain (Figure 4A). To examine the
expression of CYP9Q3 at higher resolution, we used in situ
hybridization with digoxigenin-labeled RNA probes to localize
CYP9Q3 expression in the brain andMalpighian tubules. This re-
vealed thatCYP9Q3 is expressed at particularly high levels in the
proximal regions of Malpighian tubules and where they join the
midgut-hindgut junction and in several structures of the honey-
bee brain, including the optic and antennal lobes and the mush-
room bodies (Figures 4B and 4C). Malpighian tubules are the
functional insect equivalents of vertebrate kidneys, and these
A B
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Figure 4. Tissue-Specific Expression and Functional Characterization of Honeybee and Bumble Bee Neonicotinoid-Metabolizing P450s
(A) Relative expression (fold change) ofA. mellifera andB. terrestris thiacloprid metabolising CYP9Q genes in different tissues of worker beesmeasured by qPCR.
Significant differences (p < 0.01) in expression between tissues is denoted using letters above bars as determined by One-Way ANOVA with post hoc testing
(Benjamini and Hochberg).
(B and C) (B) Whole-mount in situ hybridization showing the distribution and abundance of the AmCYP9Q3 transcript in the brain of a worker bee in different
neuronal cells and in (C) the Malpighian tubules and distal midgut.
(D and E) Expression of green fluorescent protein in the Malpighian tubules and specific neurons of the Drosophila brain driven by the Malp-tub GAL4 line.
(F) Sensitivity of transgenic Drosophila to thiacloprid when the Malp-tub GAL4 line is used to drive expression of AmCYP9Q3. Error bars display 95% CLs.osmoregulatory and detoxifying organs absorb solutes, water,
andwastes from the surrounding haemolymph. The high expres-
sion ofCYP9Q3 in this tissue is therefore highly consistent with a
primary role in xenobiotic detoxification. The expression of
CYP9Q3 and especially CYP9Q4 in the bee brain suggests a
secondary or additional site of detoxification against xenobiotics
that cross the blood-brain barrier, and it is notable that the struc-
tures of the brain expressing CYP9Q3 have been previously
highlighted as sites of AChE activity and nAChR-like immunore-
activity [20]. Based on this finding, we explored the effect of
specifically expressing CYP9Q3 in the Malpighian tubules and
the insect brain on sensitivity to thiacloprid by exploiting the
GAL4/UAS system of Drosophila. Significant levels of thiacloprid
resistancewere observed in transgenicDrosophilawhen expres-
sion of CYP9Q3 was directed to the Malpighian tubules and
neuronal cells (ellipsoid body, pars intercerebralis, fan-shaped
and large-field neurons) (Figures 4D and 4E and 4F), demon-
strating that expression of CYP9Q3 at these sites is sufficient
to provide protection against this insecticide. Previous studieshave examined the expression of honeybee CYP9Q P450s in
different life stages of bees. For example, a recent study per-
formed RNA-seq of different tissues in honeybee foragers, older
workers which gather and process food, and nurses, young
workers that care for brood [19]. While no change was observed
in CYP9Q3 expression in the Malpighian tubules and midgut
between the two worker roles, foragers showed higher levels
of expression in the mandibular and hypopharyngeal glands
[19]. These findings were consistent with a second study, which
examined the expression of CYP9Q1–3 in the legs and antennae
of newly eclosed workers, nurses, and foragers and observed a
pattern of increased expression with age [21]. The greater
expression of these P450s in foragers is consistent with their
increased exposure to xenobiotics compared to nurses, and
their elevated expression in tissues that mediate nectar process-
ing suggests that they may provide a first line of defense against
dietary xenobiotics.
Sequencing of the honeybee genome and the discovery that it
contains a reduced number of genes encoding detoxificationCurrent Biology 28, 1137–1143, April 2, 2018 1141
enzymes (includingP450s) led to the suggestion that beesmaybe
particularly sensitive to xenobiotics, including pesticides [22].
However, a subsequent meta-analysis of available toxicological
data revealed that honeybees are, in fact, nomore sensitive to in-
secticides than other insect species [23]. Both honeybees and
bumble bees have undergone millions of years of selection to
evolve mechanisms to overcome the diverse array of toxic com-
pounds that occur naturally in their environment [6]. Although
this does not include the relatively recently introduced synthetic
insecticides, our study, in combination with previous work [15],
demonstrates that these existing detoxification pathways can
be recruited to protect bees from pesticides if sufficient similarity
exists between their native substrate(s) and the synthetic com-
pound in question. In this regard, although the diversity of native
substrates that the CYP9Q subfamily can metabolize is not fully
understood, all members of this subfamily in honeybees have
been shown to metabolize the plant secondary metabolite quer-
cetin with high efficiency, a flavonoid that is present in pollen
and nectar, which inhibits mitochondrial ATP synthase [15].
In conclusion, these data demonstrate that the CYP9Q family
of both honeybees and bumble bees contains critically important
enzymes that define their sensitivity to neonicotinoids. This
finding illustrates the importance of considering bee xenobiotic
biotransformation pathways to predict, and potentially influence,
the pharmacological and toxicological outcomes of insecticide
use. For example, the knowledge and tools developed in this
study can be harnessed to avoid negative pesticide-pesticide in-
teractions [24] due to inhibition of these key defense systems.
Furthermore, our findings, and those of previous studies that
have uncovered the molecular and biochemical basis of pesti-
cide selectivity [15, 25–29], can facilitate the development of
compounds that show high efficacy against crop pests but low
toxicity to nontarget beneficial insects. In this regard, the recom-
binant enzymes and transgenic Drosophila lines developed in
our study can be used as screening tools to assess themetabolic
liability of future insecticidal lead compounds and so ensure that
they are rapidly broken down by these major xenobiotic detoxi-
fying enzymes.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Insects
Adult honeybees were obtained from open hives during the summer of 2014-2016 that were maintained pesticide-free by bee
keepers at Bayer AG, CropScience Division, Monheim, Germany. Bumblebee colonies were purchased from Agralan UK Ltd and
maintained in constant darkness at 25C, 50% RH. The colonies were fed ad libitum on the nectar substitute, Biogluc, and pollen
was supplied to colonies every 2 days.
The Drosophila melanogaster stock 13-20 [‘‘y1w67c23; P attP40 25C6,’’ ‘‘1;2’’] obtained from the University of Cambridge was used
to create all transgenic lines. Virgin females of this line were crossed to males of the Act5C-GAL4 strain [‘‘y[1] w[*]; P(Act5C-GAL4-w)
E1/CyO,’’’’1;2’’] (Bloomington Stock Center) to activate transgene expression (see below for description of methods). The
Malp-GAL4 strain [w[*]; P{w[+mW.hs] = GawB}c42] (Bloomington Stock Center) which expresses GAL4 in the Malpighian tubules
and specific neuronal cells (ellipsoid body, pars intercerebralis, fan shaped and large field neurons), was used to drive the expression
of CYP9Q3 in these tissues. The UAS-GFP strain [w1118; P{w+mC = UAS-GFP.nls}14] (Bloomington Stock Center) was used to visu-
alize the sites of expression driven by Act5C-GAL4 andMalp-GAL4 drivers. All flies were reared on NutriFly food (NLS) at 24C. Only
female flies 2-5 days post eclosion were used for insecticide bioassays.
Insect cell lines
The Sf9 and High Five insect cell lines (ovarian cells from Spodoptera frugiperda and Trichoplusia ni respectively) were maintained in
suspension culture under serum-free conditions at 27C containing 25 mg/ml-1 gentamycin in SF-900 II SFM (GIBCO) and Express
Five SFM (GIBCO), respectively.Current Biology 28, 1137–1143.e1–e5, April 2, 2018 e2
METHOD DETAILS
Insecticide bioassays of A. mellifera and B. terrestris
Acute contact insecticide assays were performed on female A. mellifera following standard methods OECD 2013 [30]. Bioassays of
B. terrestriswere based on the OECD guidelines developed for honeybees [30] but with bees assayed in individual Nicot cages. Bees
were starved of sucrose solution for up to 2 hr to encourage feeding during the experiment. Individual B. terrestriswere fed with 20 ul
of insecticide-sucrose solution at concentrations of 0.01, 0.1, 1, 10 and 100 ppm for imidacloprid and 10, 50, 100, 500 and 1000 ppm
for thiacloprid. Controls were fed a solution of sucrose containing a concentration of acetone matching that of the highest treatment
concentration. After 4-6 hr the syringes were assessed to see if bees had consumed the insecticide-sucrose solution. Those that had
not consumed all of the solution were excluded from the experiment. Mortality was assessed 48 hr after feeding and lethal concen-
trations (LC50 values) were calculated by probit analysis using Genstat version 16 (VSN International). For synergist bioassays,
B. terrestris or A. mellifera workers were first treated with 20 mg of piperonyl butoxide or 1 mg of aminobenzotriazole applied to
the dorsal thorax. Synergist bioassays included an additional control group treated only with the synergist. 1 hr after synergist appli-
cation, bees were then treated with the appropriate insecticide dosage as above.
Receptor binding studies
[3H]imidacloprid (specific activity 1.406 GBq mmol1) displacement studies were conducted using membrane preparations isolated
from frozen (80C) honeybee and bumble bee heads, respectively, following previously published protocols [9]. Briefly, bee heads
weighing 10cg were homogenized in 200cml ice-cold 0.1cM potassium phosphate buffer, pH 7.4 containing 95cmM sucrose using a
motor-driven Ultra Turrax blender. The homogenate was then centrifuged for 10cmin at 1200cg and the resulting supernatant filtered
through five layers of cheesecloth with protein concentration determined using Bradford reagent (Sigma) and bovine serum albumin
(BSA) as a reference. Assays were performed in a 96-well microtiter plate with bonded GF/C filter membrane (Packard UniFilter-96,
GF/C) and consisted of 200 mL of homogenate (0.48cmg protein), 25 mL of [3H]imidacloprid (576cpM) and 25 mL of competing ligand.
Ligand concentrations used ranged from 0.001 to 10c000cnM andwere tested at least in duplicate per competition assay. The assay
was started by the addition of homogenate and incubated for 60cmin at room temperature. Bound [3H]imidacloprid was quantified by
filtration into a second 96-well filter plate (conditioned with ice-cold 100cmMpotassium phosphate buffer, pH 7.4 (including BSA 5cg
liter1)) using a commercial cell harvester (Brandel). After three washing steps (1cml each) with buffer the 96-well filter plates were
dried overnight. Each well was then loaded with 25 mL of scintillation cocktail (Microszint-O-Filtercount, Packard) and the plate
counted in a Topcount scintillation counter (Packard). Non-specific binding was determined using a final concentration of 10cmM
unlabelled imidacloprid. All binding experiments were repeated twice using three replicates per tested ligand concentration. Data
were analyzed using a 4 parameter logistic non-linear fitting routine (GraphPad Prism version 7 (GraphPad Software, CA, USA)) in
order to calculate I50-values (concentration of unlabelled ligand displacing 50% of [
3H]imidacloprid from its binding site).
Functional expression of bee P450s
All bee P450 (see Table S3 for accession numbers) and house fly NADPH-dependent cytochrome P450 reductase (CPR) (GenBank
accession number Q07994) genes were obtained by gene synthesis (Geneart, CA, USA) and inserted into the pDEST8 expression
vector (Invitrogen). Codon optimization of all bee genes was used to optimize expression in lepidopteran cell lines. The PFastbac1
vector with no inserted DNA was used to produce a control virus. The recombinant baculovirus DNA was constructed and trans-
fected into Trichoplusia ni (High five cells, Thermo Fisher) using the Bac-to-Bac baculovirus expression system (Invitrogen) according
to the manufacturer’s instructions. The titer of the recombinant virus was determined following protocols of the supplier. High Five
cells grown to a density of 2 3 106 cells ml-1 were co-infected with recombinant baculoviruses containing each bee P450 and CPR
with a range of MOI (multiplicity of infection) ratios to identify the optimal conditions. Control cells were co-infected with the bacu-
lovirus containing vector with no insert (ctrl-virus) and the recombinant baculovirus expressing CPR using the sameMOI ratios. Ferric
citrate and d-aminolevulinic acid hydrochloride were added to a final concentration of 0.1 mM at the time of infection and 24 h after
infection to compensate the low levels of endogenous heme in the insect cells. After 48 h, cells were harvested, washed with PBS,
andmicrosomes of themembrane fraction prepared according to standard procedures and stored at80C [31]. Briefly, pellets were
homogenized for 30 s in 0.1M Na/K-phosphate buffer, pH 7.4 containing 1mM EDTA and DTT and 200mM sucrose using a Fastprep
(MP Biomedicals), filtered throughmiracloth and centrifuging for 10min at 680 g at 4C. The supernatant was then centrifuged for 1 h
at 100,000 g at 4C, with the pellet subsequently resuspended in 0.1M Na/K-phosphate buffer, pH 7.6 containing 1mM EDTA and
DTT and 10% glycerol using a Dounce tissue grinder. P450 expression and functionality was estimated by measuring CO-difference
spectra in reduced samples using a Specord 200 Plus Spectrophotometer (Analytik Jena) and scanning from 500 nm to 400 nm [31].
The protein content of samples was determined using Bradford reagent (Sigma) and bovine serum albumin (BSA) as a reference.
Metabolism assays and UPLC-MS/MS analysis
Metabolism of thiacloprid, imidacloprid and acetamiprid were assayed by incubating each recombinant bee P450/CPR (50-80mg of
protein/assay) or ctrl-virus/CPR microsomes in 0.1 M potassium phosphate buffer with an NADPH-regenerating system (Promega;
1.3 mM NADP+, 3.3 mM glucose-6-phosphate, 3.3 mM MgCl2, 0.4 U mL
-1 glucose-6- phosphate dehydrogenase) and substrate
(10-25 mM; 0.78125 – 200 mM for enzyme kinetics) at 30C for 2 h (A. mellifera P450s all insecticides), or 27C for 45 min
(B. terrestris P450s for imidacloprid and thiacloprid) or 60 min (B. terrestris P450s for acetamiprid). The total assay volume wase3 Current Biology 28, 1137–1143.e1–e5, April 2, 2018
200 mL using three replicates for each data point. Microsomes incubatedwithout NADPH served as a control. The assaywas stopped
by the addition of ice-cold acetonitrile (to 80%final concentration), centrifuged for 10min at 3000 g and the supernatant subsequently
analyzed by tandem mass spectrometry as described previously [18]. For the chromatography on a Waters Acquity HSS T3 column
(2.1x50mm, 1.8mm), acetonitrile/water/0.1% formic acid was used as the eluent in gradient mode. For detection and quantification in
positive ion mode, the MRM transitions 253 > 186, 269 > 202 (thiacloprid, OH-thiacloprid), 256 > 175, 272 > 191 (imidacloprid,
OH-imidacloprid) and 223 > 126, 209 > 126 (acetamiprid and N-desmethyl acetamiprid) were monitored. The peak integrals were
calibrated externally against a standard calibration curve. The linear range for the quantification of neonicotinoid insecticides and
their hydroxylated (thiacloprid and imidacloprid) and N-desmethylated (acetamiprid) metabolites was 0.1 to 1000 ng mL-1. Recovery
rates of parent compounds using microsomal fractions without NADPH were normally close to 100%. Substrate turnover from two
independent reactions were plotted versus controls and Michaelis-Menten kinetics determined using GraphPad Prism version 7
(GraphPad Software, CA, USA).
Functional activity of recombinant P450s against fluorescent model substrates
The activity of individual A. mellifera and B. terrestris recombinant P450s were tested against seven fluorescent model substrates (all
purchased from Sigma); 7-methoxy-coumarin (MC), 7-Methoxy-4-(tri-fluoromethyl)-coumarin (MFC), 7-ethoxy-coumarin (EC),
7-benzyloxy-4-(trifluoromethyl)-coumarin (BFC), 7-ethoxy-4-trifluoro-methylcoumarin (EFC), 7-benzyloxymethoxy-4-trifluoromethyl
coumarin (BOMFC), and 7-p-methoxy-benzyloxy-4-trifluoro coumarin (MOBFC). Assays were carried out in black flat-bottomed 96-
well plates in a 100 mL reaction containing 2 pmol of P450 per 50 mg of protein (B. terrestris) or 50 mg/well (A. mellifera), 1 mM of
NADPH (Sigma) and 50 mM of a model substrate (Sigma). Three replicates were carried out for each data point. P450s incubated
without NADPH and wells containing only potassium phosphate buffer served as controls. Samples were incubated at 25C for
45 min (B. terrestris) or 30C for 30 min (A. mellifera). Data were recorded using a SpectraMax Gemini XPS (B. terrestris) or a
SpectraMax M2 (A. mellifera) at the excitation/emission wavelength suitable for each model substrate (MC, EC at 390-465, BFC,
MFC at 410-535, EFC at 410-510 and BOMFC and MOBFC at 405-510 nm). As these substrates have a similar emission wavelength
toNADPH (460 nm) the reaction was terminated prior tomeasurement by the addition of 100mL of a stop solution (25%DMSO, 0.05M
Tris/HCL pH10, 5 mM glutathione oxidised, and 0.2 U glutathione reductase). The reactions were incubated at 25C (B. terrestris) or
30C (A. mellifera) for a further 15 min and the data were recorded at the required excitation/emission wavelengths stated above.
7-hydroxy-4-(trifluoromethyl)-coumarin (HFC) (Sigma) was used to generate a standard curve for model substrates BFC, EFC,
MFC, MOBFC, and BOMFC and 7-hydroxycoumarin (HC) (Sigma) for model substrates EC and MC. Each compound was diluted
to a range of concentrations (0, 5, 10, 15, 20, 30, 50, 60, 80 and 100 pmol) using potassium phosphate buffer. 100 mL of each con-
centration was added to each well with four replicates for each data point. 100 mL of stop solution was then added and the contents
mixed. The florescence was measured as above at the corresponding wavelengths for each model substrate. Microsoft Excel was
used to calculate the y intercept for each compound. This was then subtracted from the average fluorescence measurement of each
P450 along with the average control measurements.
Transgenic expression of bee P450s in D. melanogaster
A. mellifera (AmCYP9Q1–3) and B. terrestris (BtCYP9Q4–5) genes were codon optimized for D. melanogaster expression and cloned
into the pUASTattB plasmid (GenBank: EF362409.1). pUASTattB-CYP9Q1–3 and pUASTattB-CYP9Q4–5 constructs were injected
into preblastodermal embryos of a D. melanogaster strain carrying an attP docking site on chromosome 2 (attP40) and the phiC31
integrase gene under the control of the vasa regulatory region on the X chromosome [y w M(eGFP, vas-int, dmRFP)ZH-2A; P{CaryP}
attP40] [32]. The presence of the transgene was confirmed by PCR and sequencing. Genomic DNA was extracted from pools of 10
flies for each line using the Plant DNeasy Mini kit (QIAGEN) following the manufacturers protocol. 20 ng of this DNA was used as
template in PCR using Phusion DNA polymerase (Thermo) following the manufacturers protocol and the primers listed in
Table S2. Thermocycling conditions consisted of an initial denaturation step at 98C for 30 s, followed by 35 cycles of 98C for
10 s, 55C for 20 s, 72C for 1 min, and a final extension at 72C for 5 min. Products were direct Sanger sequenced using the primers
detailed in Table S2. Fly lines were made homozygous for the transgene integrations. The GAL4/UAS systemwas used to control the
expression of bee CYP9Q genes in transgenic D. melanogaster. The strain Act5C-GAL4 [y1 w*; P{Act5C-GAL4-w}E1/CyO] was used
to drive the expression of CYP9Q1–3 and CYP9Q4–5 genes ubiquitously under the control of the Actin5C regulatory sequence. The
Malp-GAL4 strain [w[*]; P{w[+mW.hs] = GawB}c42], which expresses GAL4 in the Malpighian tubules and specific neuronal cells
(ellipsoid body, pars intercerebralis, fan shaped and large field neurons), was used to drive the expression of CYP9Q3 in these tis-
sues. The UAS-GFP strain [w1118; P{w+mC = UAS-GFP.nls}14] was used to visualize the sites of expression driven by Act5C-GAL4
andMalp-GAL4 drivers. Transgene expressionwas confirmed by qPCRas previously described [33]. Total RNAwas extracted from 4
pools of 10 adult flies of each line using the ISOLATE II RNA Mini Kit (Bioline) and reverse transcribed to cDNA using Superscript III
reverse transcriptase (Invitrogen) following manufacturer protocols in both cases. PCR reactions (20 mL) contained 10 ng of cDNA,
10 mL of SYBR Green JumpStart Taq Readymix (Sigma), and 0.25 mm of each primer. Samples were run on a Rotor-Gene 6000
(Corbett Research) using temperature cycling conditions of: 2 min at 95C followed by 40 cycles of 95C for 15 s, 57C for 15 s
and 72C for 20 s. Data were analyzed in Microsoft Excel according to the DDCT method [34] using the RPL11 reference gene for
normalization [33]. Full dose response bioassays were performed by feeding adult female flies a range of insecticide concentrations
dissolved in sugar/agar. At least three replicates of 20 flies were carried out for each concentration. LC50 values were calculated as
above.Current Biology 28, 1137–1143.e1–e5, April 2, 2018 e4
Expression profiling of bee P450s
Bees were dissected and total RNA was prepared from tissues of single female bees using the PicoPure RNA Isolation Kit
(ThermoFisher) as described by the manufacturer. 0.5 mg were used for cDNA synthesis using iScript (Biorad) according to the
manufacturer’s instructions. PCR reactions (10 mL) contained 2.5 mL of cDNA (7.8 ng), 5 mL of SsoAdvanced Universal SYBR Green
Supermix (BioRad), and 0.25 mM of each primer (Table S2). Samples were run on a CFX384 Real Time System (BioRad) using the
temperature cycling conditions of: 3 min at 95C followed by 39 cycles of 95C for 15 s, 64C for 15 s and 60C for 15 s. A final
melt-curve step was included post-PCR (ramping from 65-95Cby 0.5C every 5 s) to confirm the absence of any non-specific ampli-
fication. The efficiency of PCR for each primer pair was assessed using a serial dilution of 25 ng to 0.04 ng of cDNA. Each qPCR
experiment consisted of at least 7 independent biological replicates with three technical replicates for each. Data were analyzed
according to the DDCT method [34] using qbase+ Version: 3.1 (Biogazelle). The expression level was normalized to two validated
reference genes [35–37] for each species. Rpl32 (ribosomal protein L32), GADPH (glyceraldehyde 3-phosphate dehydrogenase),
PAL2 (phospholipase A2) and EEF1A (elongation factor 1-alpha) of the honeybee and bumble bee respectively (Table S2). In situ
hybridization with antibody labeled RNA probes was used to visualize the expression of CYP9Q3 in the brain and Malpighian tubules
of honeybees. Fragments of700 bpwere amplified from honeybee cDNA by PCR using gene-specific primers (Table S2) containing
the T7 promoter sequence at the end and served as templates for synthesis using the T7 RNA polymerase and digoxigenin-labeled
ribonucleotides. Digoxigenin-labeled riboprobes were purified and hydrolyzed into 100-400 bp fragments with 0.1M sodium carbon-
ate. Tissues from cold-anaesthetized bees were then dissected in PBS, fixed overnight in 4% paraformaldehyde and dehydrated in a
methanol series. Before hybridization tissues were rehydrated in PBS/0.1% Tween, pre-incubated overnight at 55C in hybridization
buffer (50% formamide, 5xSSC, 0.1% Tween, 100 mg ml-1 yeast tRNA, 200 mg ml-1 salmon sperm, 50 mg ml-1 heparin) and then
hybridized with the diluted riboprobes (1.0-4.0 ug ml-1 in hybridization buffer) at 55C. After extensive post-hybridization stringency
washes samples were pre-blocked in 1% BSA for at least 1 h prior to overnight incubation with the pre-adsorbed alkaline phospha-
tase labeled antidigoxygenin antibody (1:2000 dilution in PBS/1% BSA/0.1% Tween). The signal was visualized with NBT/BCIP
alkaline phosphatase substrates according to the manufacturer’s instructions.
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analyses were performed in GraphPad Prism 7 (GraphPad Software) apart fromqPCR analsyses, whichwere performed
in qbase+ Version 3.1 (Biogazelle). Significant differences in expression in all qPCR experiments were determined using one-way
ANOVA with post hoc testing (Benjamini and Hochberg). Significant differences in activity of recombinant P450s against thiacloprid
and imidacloprid was determined using a Welch’s t test. Statistical details of experiments (value of n, precision measures and
definitions of significance) are provided in figure legends.
DATA AND SOFTWARE AVAILABILITY
The sequences reported in this paper are all available in online sequence repositories (see Table S3).e5 Current Biology 28, 1137–1143.e1–e5, April 2, 2018
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Figure S1. LC-MS/MS analysis of thiacloprid metabolism by CYP9Q3. Related to 
Figure 2.   LC-MS analysis of thiacloprid metabolism. Typical MRM chromatograms of the 
CYP9Q3 catalysed formation of OH-thiacloprid with and without NADPH. Ion transition of 
thiacloprid [M+H]+ 253 and OH-thiacloprid [M+H]+ 269 to their fragments m/z 186 and m/z 
202 are measured, respectively. 
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 CYP9Q1 CYP9Q2 CYP9Q3   CYP9Q4 CYP9Q5 
Vmax 3,92 ±0,08 44,31±1,01 607,8±5,48 Vmax 18,94±0,64 4,29±0,71 
Km 17,83±1,08 5,65±0,49 3,92±0,14 Km 11,82±1,51 30,04±14,85 
 
 
Figure S2. Michaelis-Menten kinetics of thiacloprid hydroxylation by A. mellifera and 
B. terrestris metabolising P450s analysed by non-linear regression. Related to Figure 
2. A, B, Michaelis-Menten kinetics plots of thiacloprid hydroxylation catalyzed by 
AmCYP9Q1-3 (A) and BtCYP9Q4-5 (B). The apparent Km and Vmax values for thiacloprid are 
indicated below the respective graphs. Data points are mean values ± SD (n=3). 
 
 
 
 
 
 
 
 
 
 
  
Figure S3. Heat map showing the levels of sequence identity between A. mellifera 
CYP9Q1-3 and B. terrestris CYP9 genes. Related to Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Application Insecticide Synergist 
LD50 
(μg/bee) 
95% CI Slope ± SE 
Synergism 
Ratio 
Topical 
Imidacloprid None 0.38 0.12 - 1.45 0.6 0.11 n/a 
Thiacloprid None >100 n/a n/a n/a n/a 
Oral 
Imidacloprid 
None 0.038 
0.012 - 
0.075 
1.5 0.44 n/a 
PBO 0.032 
0.016 - 
0.05 
1.9 0.41 1.2 
Thiacloprid 
None 19.68 
13.45 - 
26.88 
1.8 0.26 n/a 
PBO 4.73 2.55 - 7.71 1.4 0.24 4.2 
 
Table S1. Sensitivity of Bombus terrestris to imidacloprid and thiacloprid in 
insecticide bioassays. Related to Figure 1.  Neonicotinoid acute contact and acute oral 
LD50 values (95% confidence intervals) and slope (SE) for Bombus terrestris 48 hours 
after application of insecticide. Synergism ratio is also shown, where the P450 inhibitor 
piperonyl butoxide (PBO) was used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primers Sequence Use 
AmCyp9Q3 F1 5'-GATGTGCGTCGAGAGTTTCC-3' qPCR (CYP9Q3) 
AmCyp9Q3 R1 5'-CTGTCCGGGTCGAATTTGTC-3' qPCR (CYP9Q3) 
AmCyp9Q2 F1 5'-ATGGAAGGAGCACAGGAACA-3' qPCR (CYP9Q2) 
AmCyp9Q2 R1 5'-ACGTCGTTGGTGTATCTGGT-3' qPCR (CYP9Q2) 
AmCyp9Q1 F1 5'-GGAGGAGGGGAAGAGAGGTA -3' qPCR (CYP9Q1) 
AmCyp9Q1 R1 5'-CCTCCTGAAGCCTCTGTTGA-3' qPCR (CYP9Q1) 
AmRpl32 F1 5'-AGTAAATTAAAGAGAAACTGGCGTAA-3' qPCR (reference gene) 
AmRpl32 R1 5'-TAAAACTTCCAGTTCCTTGACATTAT-3' qPCR (reference gene) 
AmGADPH F1 5'-ACCTTCTGCAAAATTATGGCGA-3' qPCR (reference gene) 
AmGADPH R1 5'-CACCTTTGCCAAGTCTAACTGTTAAG-3' qPCR (reference gene) 
BtCyp9Q4 F1 5’-TATTCCACCAACGCCACTGT-3’ qPCR (CYP9Q4) 
BtCyp9Q4 R1 5’-GGTCCACTTCCTTGTATGCG-3’ qPCR (CYP9Q4) 
BtCyp9Q5 F1 5’-CCTACGATGCTCTAAGCGAGATG-3’ qPCR (CYP9Q5) 
BtCyp9Q5 R1 5’-ATTCTCGTAATATTGAGGATCGCG-3’ qPCR (CYP9Q5) 
BtPal F1 5'-TGTCGGTATCTACGCGCCTG-3' qPCR (reference gene) 
BtPal R1 5'-TTGGTGGATGCTTGTCAGTC-3' qPCR (reference gene) 
BtEEF1A F1 5'-AGAATGGACAAACCCGTGAG-3' qPCR (reference gene) 
BtEEF1A R1 5'-CACAAATGCTACCGCAACAG-3' qPCR (reference gene) 
D099 pUAST F TCACTGGAACTAGGCTAGCA-3' Sequence validation of 
transgenic flies 
 
D102 pUAST F 5'-GGATCCAAGCTTGCATGCCTG-3' sequence validation of 
transgenic flies 
 
D100 pUAST R 5'-AAAGGCATTCCACCACTGCT-3' sequence validation of 
transgenic flies 
 
D101 pUAST R 5'-CCACCACTGCTCCCATTCAT-3' sequence validation of 
transgenic flies 
 
AmCyp9Q3 F3  5'-TGGAAGGAGCACAGGAACAT-3' in situ hybridisation (CYP9Q3) 
AmCyp9Q3 R6-T7 5'-TAATACGACTCACTATAGGGAGATGATCACGGCGTCCATGTAT-
3' 
In situ hybridisation (CYP9Q3) 
 
Table S2. Sequence of oligonucleotide primers for, PCR, qRT-PCR and in situ 
hybridization used in this study. Related to STAR methods. 
 
 
 
 
 
 
 
 
 
 
Species 
Gene 
name 
Accession 
Number 
Bombus terrestris CYP9Q4 XP_003393377 
Bombus terrestris CYP9Q5 XP_003393376.1 
Bombus terrestris CYP9P1 XP_020718545.1 
Bombus terrestris CYP9P2 XP_003393388.3 
Bombus terrestris CYP9R1 XP_003393379.1  
Apis mellifera CYP9Q1 XP_006562364 
Apis mellifera CYP9Q2 XP_392000  
Apis mellifera CYP9Q3 XP_006562363  
Apis mellifera CYP9R1 GB16803 
Apis mellifera CYP9S1 XP_016771487 
Apis mellifera CYP336A1 XP_001119981 
Apis mellifera CYP9P1 XP_006562365 
Apis mellifera CYP9P2 GB19055 
Apis mellifera CYP6AQ1 NP_001191991  
Apis mellifera CYP6AR1  XP_623362 
Apis mellifera CYP6AS1 GB16899 
Apis mellifera CYP6AS2 GB19197 
Apis mellifera CYP6AS3 GB15681 
Apis mellifera CYP6AS4 XP_395671 
Apis mellifera CYP6AS5 DQ232888 
Apis mellifera CYP6AS7 XP_006565064 
Apis mellifera CYP6AS8 XP_006565076 
Apis mellifera CYP6AS10 XP_016771320 
Apis mellifera CYP6AS11 XP_016771191 
Apis mellifera CYP6AS12 XP_397347 
Apis mellifera CYP6AS13 GB17831 
Apis mellifera CYP6AS15 XP_623595 
Apis mellifera CYP6AS17 XP_006565063 
Apis mellifera CYP6AS18 XP_006565063 
Apis mellifera CYP6BC1 XP_016766476 
Apis mellifera CYP6BD1 XP_006564499 
Apis mellifera CYP6BE1 XP_624795 
 
Table S3. Accession numbers of P450 sequences functionally expressed in this study. 
Related to STAR methods. 
